Sentiment-Signal
19,2
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
89.4
13D-Filing vorhanden
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Unternehmen & Branche
| Name | Cingulate Inc. |
|---|---|
| Ticker | CING |
| CIK | 0001862150 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 26,4 Mio. USD |
| Beta | -0,77 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -22,449,911 | -4.44 | 15,073,263 | 2,508,907 | |
| 2025-09-30 | 10-Q | -7,341,062 | -1.35 | 10,518,892 | 3,473,686 | |
| 2025-06-30 | 10-Q | -4,983,261 | -1.09 | 13,468,208 | 5,511,874 | |
| 2025-03-31 | 10-Q | -3,852,678 | -1.04 | 12,469,588 | 5,930,820 | |
| 2024-12-31 | 10-K | -16,559,605 | -10.86 | 14,864,489 | 7,455,505 | |
| 2024-09-30 | 10-Q | -4,125,643 | -2.34 | 13,580,104 | 12,037,563 | |
| 2024-06-30 | 10-Q | -3,230,385 | -5.47 | 5,126,907 | 3,083,772 | |
| 2024-03-31 | 10-Q | -2,972,477 | -7.21 | 5,494,515 | 3,216,119 | |
| 2023-12-31 | 10-K | -23,534,947 | -311.99 | 3,491,436 | -6,869,429 | |
| 2023-09-30 | 10-Q | -5,979,054 | -72.60 | 5,870,258 | -96,334 | |
| 2023-06-30 | 10-Q | -6,616,309 | -6.79 | 5,227,447 | -6,098,521 | |
| 2023-03-31 | 10-Q | -4,004,887 | -7.08 | 7,162,957 | 81,614 | |
| 2022-12-31 | 10-K | -17,676,232 | -29.35 | 11,405,057 | 3,882,022 | |
| 2022-09-30 | 10-Q | -4,027,247 | -0.36 | 15,376,675 | 8,366,532 | |
| 2022-06-30 | 10-Q | -4,040,447 | -0.36 | 13,803,854 | 12,184,874 | |
| 2022-03-31 | 10-Q | -5,003,511 | 18,432,681 | 16,018,601 | ||
| 2021-12-31 | 10-K | -20,709,991 | 22,886,257 | 20,843,542 | ||
| 2021-09-30 | 10-Q | -15,290,048 | 3,079,151 | |||
| 2021-06-30 | 10-Q | -1,432,295 | 1,899,380 | |||
| 2021-03-31 | 10-Q | -1,333,923 | 1,344,035 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.